Maple Biosciences is developing new diagnostic instruments based on biosensor technology that will be able to perform highly complex lab tests in a matter of minutes. To achieve our development goals, MedMira has acquired SensorChem International, a company that was founded based on research conducted by Professor Michael Thompson in the Department of Chemistry at the University of Toronto. Dr. Thompson is a pioneer in the field of biosensor technology and has devoted much of his career to exploring the capabilities of biosensors and their potential for commercial applications. Dr. Thompson has also invested significant efforts in securing the intellectual property for these inventions, and many patents are held or pending for the biosensor devices themselves as well as the chemistry methods required to build lab tests for use with these instruments.
Cytoplex is the pioneer of NanoBio materials, sensors, nanomaterials and microdevices for the Life Science, Medical and Process Industries. We have significant expertise in materials design with inorganic materials, polymers, biochemicals, device fabrication, and expertise in applying them to different areas of the industry. Who We Serve: Detection of Biological proteins is important for many reasons. Some of these proteins called Ion Channels have very important role to play and their malfunction causes Alzheimer's, Pain, Hypertension, epilepsy, bipolar disorder, etc. Identifying the chemicals that bind to these proteins is a very important aspect of drug discovery for pharmaceutical companies. Some proteins are responsible in indicating the health state of the human. Early detection of these proteins can aid in early detection of cancer and other diseases. Some proteins are toxic and can lead to lethal effects. Detection of such toxic proteins is of interest to environmental agencies, US defense department, US homeland security, etc. Detection of protein production in process plants is needed to understand the optimized production protocols in the bioprocess industry. What is our Technology: Our proprietary biosensors Flexion, Nanosense and FluidiXArray allow customers to process proteins, cells and perform many drug screening applications.
AnzenBio specializes in creating solutions for the detection of micro-biologicals and biological toxins and for the isolation, amplification, and analysis of nucleic acids. Our mission is to enhance both the effectiveness and practicality of bio-detection. AnzenBio's feature product is our detection platform, consisting of the BioDetector and our Biosensor Chips. Handheld and compatible with both antibody and PCR-based detection, this proprietary system offers users a singular combination of target versatility, portability, and cost-effectiveness. Whether the application is indoor-environmental, industrial, agricultural, or bioterror prevention, AnzenBio's detection platform can be employed to effectively monitor for the biological targets in question. AnzenBio is located in Salt Lake City, Utah between the Wasatch Mountain Range and the Great Salt Lake.
Physiologic Communications, LLC (PhysioComm), based in Rochester, NY is a biotechnology company that provides advanced diagnostic, monitoring and therapeutic solutions to the biomedical community. Our technology accelerates and redefines existing approaches to drug discovery paradigms and provides for improving the safety and efficacy of the compounds during the early stages when critical decision are made. PhysioComm applies the latest basic and clinical evidence with technology to the creation of implantable biosensors that help researchers treat disease, alleviate pain, and save lives.
Applied Enzyme Technology Ltd (AET) is a company with core expertise in protein stabilisation. Application of our expertise and patented technology has resulted in the successful stabilisation of many enzymes spanning a wide variety of applications. Our research and development programme continues to generate and characterise novel tools for the stabilisation of labile enzymes of interest in many different industries including the pharmaceutical and environmental industries. AET has licensed its stabilisation technology into companies world-wide including Amersham Pharmacia Biotech AB, Yellow Springs Instruments Inc, Biocatalysts Ltd., Symbollon Inc. and Capital Controls Ltd. Applied Enzyme Technology Ltd. was established in 1994 to exploit a portfolio of intellectual property generated from research programmes initiated in the School of Biochemistry and Molecular Biology at the University of Leeds. AET was granted a SMART 1 Award from the Department of Trade and Industry in 1995 to develop enzyme based kits with novel dye detection systems. As a straight follow on from the 1st SMART award, a second stage SMART 2 grant was won in 1996 to extend the range of enzyme stabilisation systems. In 1996 AET was invited to participate as a full partner in an EU funded project, and since then has been involved in 4 subsequent EU funded projects and one as project Co-ordinator. The latest involvement being as a subcontractor on a project that started at the beginning of 2001. In June 2001 a leading electronic sensor materials company, Gwent Electronic Materials Ltd., part of the Gwent Group, invested heavily in AET and as a consequence AET relocated near Cardiff in South Wales. AET now runs as an independent subsidiary of Gwent Electronic Materials Ltd. where our core business remains the same. The synergy between the two companies brings together the expertise in enzyme stabilisation of AET and the expertise in the design and production of specialist electronic sensor materials attached to Gwent Electronic Materials Ltd. Gwent Sensors Ltd., another company within the Gwent Group, specialises in development of disposable sensor technology. With access to all the above technology, all 3 companies are in the in the unique position to be able to offer a "1 Stop Shop" for the development and production of biosensors. This has been taken one step further, as the Gwent Group can now provide the complete biosensor package including specialised instrumentation due to close collaboration with specialist instrumentation development companies.
ACEA Biosciences has pioneered the development of high-performance microelectronic systems for cell-based assays. ACEA has developed and is marketing on a world-wide basis its microplate-based biosensor platform for a variety of applications in drug development, toxicology, cancer research, and medical microbiology and virology. ACEA's products are designed to meet the increasing needs of the life science research and drug discovery markets by providing cost-effective, automated, high content, real time detection systems that simplify complex cell-based assay procedures and increase productivity. ACEA's current product portfolio includes the RT-CES® microplate biosensor platform featuring 16 well and 96 well plates and individual workstations. In addition, a 6 X 96 multi-plate® station is now available to increase the assay throughput. Using the same microelectronic sensor technology, the revolutionary RT-CIMÔ System allows researchers to study the invasiveness of cancer cells in a highly quantitative, microplate- based, label-free, cost effective assay. With its international reach, ACEA Biosciences works closely with scientists throughout the world. Hangzhou, China is the site of ACEA's world-class manufacturing operations. A network of distributors assures the timely sales, service, and support of ACEA's growing product line throughout the world. ACEA Biosciences headquarter is in San Diego, California.
Aresa A/S is a Denmark-based company active in the plant biotechnology industry. It focuses on the BioSensor patent-protected technology. The activities connected with the BioSensor technology cover a controlled color change in plants, by use of such products as RedDetect, RedDetect UXO and RedScreen. The technology is based on the plant Arabidopsis thaliana (thale cress). The Company operates through two wholly owned subsidiaries, Aresa Biodetection ApS and Aresa BioPharma ApS. Aresa BioPharma ApS is a dormant company. Aresa A/S was founded in 2001 by Carsten Meier, and has its scientific outset from the Institute of Molecular Biology and Physiology, Copenhagen University, Denmark.
Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The Company pioneered the use of B-Galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide.
Privacy Policy | Terms and Conditions | Do Not Sell My Personal Information | Websites Directory
Copyright © 2022 kwtbox.com. All Rights Reserved. US Business Directory